This advanced disease stage exhibits clonal, genomic, and molecular heterogeneity, often featuring additional chromosomal aberrations and mutations in the BCR::ABL1 kinase domain and/or other leukemia-related genes. This evidence concerns the gene ABL1 and leukemia.